Center for Technology Commercialization

Health & Bio

Program: Medical College of Wisconsin

Next‑Generation Lyme Disease Vaccine

Technology Sectors:

Longer‑term protection for people and pets at risk As Lyme risk continues to expand, this innovation points toward a new generation of vaccines designed for durability—not short‑lived immunity. The approach aims to provide broader, longer‑term protection for both people and pets in regions where Lyme disease is becoming a persistent and growing threat.

Program: Versiti

Lipid‑Lowering Peptide for Cardiovascular Disease

Technology Sectors:

Addressing the heart‑disease risk that today’s drugs leave behind Even with medication, millions remain at risk for cardiovascular events. This innovation points toward a new class of therapies that address the full range of harmful blood lipoproteins—opening more complete and durable protection for patients underserved by today’s standard treatments.

Program: Versiti

Front-Line Antiviral Protection Platform

Technology Sectors:

Stopping Respiratory Infections Before They Take Hold This intranasal platform reimagines antiviral protection by acting at the body’s front line—where respiratory viruses begin infection. By anchoring protection directly to airway cells, it enables longer‑lasting defense and a flexible approach that can be rapidly adapted to new and emerging viral threats.